Author: Anna Smith

The launch is a “major stepping stone” towards providing “widely available, clinically proven, and user friendly artificial pancreas technology to people with type I diabetes.”

The decision follows advice from the trial’s independent data monitoring committee.

Eli Lilly and AbCellera have plans to co-develop antibody products, and Elsevier is set to make all of its research and data content available on PubMed.

Half of the public aren’t even aware that conditions like type II diabetes may be preventable.

When added to Lynparza, the drug didn’t meet the trial’s primary endpoint.